Last Updated: November 19, 2026

ENSPRYNG Drug Profile

« Back to Dashboard


Summary for Tradename: ENSPRYNG
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for ENSPRYNG
Recent Clinical Trials for ENSPRYNG

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Hoffmann-La RochePhase 3

See all ENSPRYNG clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENSPRYNG Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENSPRYNG Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ENSPRYNG Derived from Patent Text Search

No patents found based on company disclosures

Enspryng Market Dynamics, Revenue Trajectory, Exclusivity, and Competitive Outlook

Last updated: October 30, 2026

Enspryng, Roche’s satralizumab, is an IL-6 receptor inhibitor approved for aquaporin-4 immunoglobulin G seropositive neuromyelitis optica spectrum disorder. The product has moved from launch-stage adoption to a growth asset within Roche’s neurology portfolio. Revenue remains modest relative to Ocrevus and Hemlibra, but the commercial profile is supported by chronic treatment, a concentrated specialist prescriber base, subcutaneous self-administration, orphan-drug economics, and pediatric expansion.

Roche-reported Enspryng sales increased from approximately CHF 0.2 billion in 2022 to approximately CHF 0.3 billion in 2023 and approximately CHF 0.4 billion in 2024. The principal risks are the small addressable population, competition from Uplizna and Soliris, treatment sequencing among approved biologics, and future biosimilar or follow-on competition after regulatory and patent protection declines.

What is Enspryng and how does satralizumab work?

Enspryng is a subcutaneous formulation of satralizumab, a humanized monoclonal antibody targeting the interleukin-6 receptor. It is administered after loading doses and then every four weeks.

Attribute Enspryng
Active ingredient Satralizumab-mwge
Drug class IL-6 receptor antagonist
Sponsor Genentech, a Roche company
Originator Chugai Pharmaceutical
Primary indication AQP4-IgG-positive neuromyelitis optica spectrum disorder
Administration Subcutaneous injection
Initial U.S. approval August 2020
FDA pathway Biologics license application
Regulatory designation Orphan drug
Main competitors Uplizna, Soliris, Ultomiris
Key clinical studies SAkuraSky and SAkuraStar

Satralizumab inhibits IL-6 signaling, a pathway involved in B-cell activity, plasmablast differentiation, antibody production, and inflammatory damage associated with AQP4-positive NMOSD. The product is used as monotherapy or with baseline immunosuppressive treatment, depending on the regulatory label and clinical setting. [1]

What is the FDA regulatory status of Enspryng?

The FDA approved Enspryng on Aug. 14, 2020, for adults with AQP4-IgG-positive NMOSD. The approval was based primarily on the SAkuraSky and SAkuraStar studies, which showed a reduction in relapse risk relative to placebo in the relevant populations. [1]

The FDA later expanded the indicated population to include pediatric patients aged 12 years and older who are AQP4-IgG seropositive. Pediatric expansion increases the treated population, although the commercial contribution is expected to develop gradually because pediatric NMOSD is rare and diagnosis is concentrated in specialty centers.

Key FDA milestones

Date Event
Aug. 14, 2020 FDA approval for adults with AQP4-IgG-positive NMOSD
2020 Orphan-drug commercial framework begins in the U.S.
Subsequent years International approvals in major markets, including Europe and Japan
2024 U.S. label expansion to patients aged 12 years and older

Enspryng is a biologic rather than a conventional small-molecule drug. Its U.S. regulatory protection is therefore governed primarily by the Public Health Service Act, the Biologics Price Competition and Innovation Act, orphan-drug provisions, pediatric exclusivity, and patent rights. It is not treated like a typical small-molecule product under the Hatch-Waxman Orange Book system.

What is the Orange Book status of Enspryng?

Enspryng does not have a conventional Orange Book listing because it is licensed as a biologic. The relevant FDA reference source is the Purple Book, which identifies licensed biologics and any interchangeable biosimilar status.

The distinction affects competitive entry:

  • A generic applicant cannot submit a standard Abbreviated New Drug Application for satralizumab.
  • A biosimilar sponsor must use the BPCIA pathway.
  • Biosimilar applicants may engage in the statutory patent-information exchange commonly called the patent dance.
  • The reference product receives 12 years of U.S. reference-product exclusivity from first licensure, subject to statutory rules.
  • Pediatric exclusivity can extend applicable exclusivity by six months when the FDA requirements are satisfied.

A future satralizumab competitor would therefore face a biosimilar development pathway, not a Paragraph IV abbreviated-application pathway.

When does Enspryng lose regulatory exclusivity?

The 12-year U.S. reference-product exclusivity period runs from the date of first licensure in August 2020. On that basis, biosimilar applications could generally become eligible in 2032, subject to the statutory reference-product framework and FDA interpretation.

The principal regulatory dates are:

Protection Approximate U.S. timing
First approval August 2020
Seven-year orphan-drug exclusivity August 2027
Potential six-month pediatric extension Up to February 2033
Twelve-year biologic reference-product exclusivity August 2032
Potential effective protection including pediatric extension Up to February 2033

Orphan exclusivity prevents approval of the same drug for the same orphan indication. It does not block all biologically different therapies, off-label use, or products with materially different indications. It also does not prevent a biosimilar from entering for a non-overlapping indication if the statutory and patent framework permits that use.

The commercial significance of the 2032-2033 period is greater than the orphan-expiry date. The twelve-year biologic exclusivity period is the more important U.S. entry barrier for a biosimilar reference-product competitor.

What patents protect Enspryng?

Enspryng is protected by a patent estate covering antibody composition, antigen binding, therapeutic use, and potentially formulation or dosing claims. The estate originated from Chugai and Roche development and commercialization activities and is jurisdiction-specific.

The most relevant claim categories are:

  1. Satralizumab antibody composition claims.
  2. Antibodies that bind the human IL-6 receptor and inhibit signaling.
  3. Use of satralizumab for NMOSD.
  4. Treatment of AQP4-IgG-positive patients.
  5. Relapse prevention and maintenance dosing.
  6. Subcutaneous administration and pharmaceutical composition claims.
  7. Manufacturing and cell-culture processes for the antibody.

Composition-of-matter and antibody-family patents are generally more important than method-of-use patents because they can cover the product itself. Method-of-use claims can still create litigation risk, particularly when a biosimilar sponsor seeks approval for the same NMOSD indication.

Publicly available regulatory and patent records do not create an Orange Book-style, single-date patent table for Enspryng. Patent expiry differs by country, patent family, terminal disclaimers, patent-term adjustments, supplementary protection certificates, and pediatric extensions. The commercial protection profile is therefore best viewed in layers rather than as one expiration date.

U.S. patent protection versus regulatory protection

Protection type Strategic role
Antibody composition claims Primary product-level barrier
Use-of-satrilizumab claims Supports indication-specific enforcement
Dosing claims May protect regimen and maintenance use
Formulation claims Can restrict specific injectable presentations
Manufacturing claims May raise process-development and CMC costs
BPCIA exclusivity Delays biosimilar filing and approval
Orphan exclusivity Blocks same-drug approval for the protected orphan use

The most important commercial window is the period between loss of orphan exclusivity in 2027 and the end of biologic exclusivity around 2032, during which patent litigation and label strategy may determine the practical timing of competition.

What is the financial trajectory for Enspryng?

Roche’s annual reports show a rapid percentage-growth profile from a small base. Reported sales have benefited from broader market availability, additional treated patients, continued use in maintenance therapy, and increased recognition of AQP4-positive NMOSD.

Fiscal year Roche-reported Enspryng sales Market interpretation
2021 Approximately CHF 0.1 billion Early launch and market access phase
2022 Approximately CHF 0.2 billion Wider specialist adoption
2023 Approximately CHF 0.3 billion Expansion in established markets
2024 Approximately CHF 0.4 billion Continued growth and pediatric opportunity

Roche reports group sales in Swiss francs. The company’s reporting convention and product-level rounding can cause minor differences between annual-report tables and third-party market databases. [2-5]

Enspryng remains a relatively small Roche product by absolute revenue, but its strategic value is higher than its current sales alone suggest. It is a chronic specialty biologic with limited direct manufacturing volume, a concentrated prescriber base, and relatively high revenue per treated patient. The product also fits Roche’s broader neurology infrastructure.

Revenue exposure

The commercial exposure is concentrated in four factors:

  • The prevalence and diagnosis rate of AQP4-positive NMOSD.
  • The share of eligible patients receiving biologic maintenance therapy.
  • Treatment selection among Enspryng, Uplizna, and complement inhibition.
  • Persistence and switching behavior after relapse, intolerance, or inadequate response.

NMOSD is rare, and not every patient with NMOSD is AQP4-IgG positive. That sharply limits the addressable market compared with multiple sclerosis, rheumatoid arthritis, or generalized autoimmune disease. Roche’s growth opportunity therefore depends more on treatment penetration and duration than on broad disease expansion.

How does Enspryng compare with Uplizna, Soliris, and Ultomiris?

Enspryng versus Uplizna

Uplizna, inebilizumab-cdon, is an anti-CD19 antibody from Viela Bio, now part of Horizon Therapeutics and Amgen. It is administered intravenously and depletes B cells more directly than satralizumab’s IL-6 receptor blockade.

Factor Enspryng Uplizna
Mechanism IL-6 receptor inhibition CD19-directed B-cell depletion
Administration Subcutaneous Intravenous
Maintenance schedule Every four weeks after loading Intermittent infusion schedule
Commercial advantage Home administration and dosing convenience Less frequent administration
Main risk Frequent injections and narrow population Infusion burden and B-cell depletion

Uplizna’s regulatory expansion into additional autoimmune indications could give Amgen greater scale and salesforce leverage. Enspryng retains a convenience advantage for patients who prefer self-injection and clinicians seeking an established IL-6 pathway therapy.

Enspryng versus Soliris and Ultomiris

Soliris and Ultomiris are complement C5 inhibitors marketed by Alexion, a subsidiary of AstraZeneca. They have strong biologic validation in complement-mediated disease but carry high cost, infusion requirements, and infection-management considerations.

Ultomiris has a longer dosing interval than Soliris. This can improve convenience relative to frequent infusion therapy but does not provide Enspryng’s subcutaneous self-administration model.

Competition is likely to be determined by:

  • Prior treatment and relapse history.
  • AQP4 antibody status.
  • Physician preference for B-cell depletion, IL-6 blockade, or complement inhibition.
  • Administration setting.
  • Payer restrictions and step-therapy rules.
  • Safety monitoring and infection risk.
  • Patient adherence to injections or infusions.

Which companies are challenging Enspryng?

No publicly reported U.S. Paragraph IV challenge applies because Enspryng is a biologic. A conventional generic challenge is not the relevant route.

Potential competitive pressure comes from three groups:

  1. Commercially approved NMOSD biologics, including Uplizna, Soliris, and Ultomiris.
  2. Biosimilar developers that may evaluate satralizumab after BPCIA filing eligibility.
  3. Pipeline companies developing next-generation B-cell, complement, or cytokine therapies.

Through the latest publicly reported information available for 2024, there was no prominent public BPCIA patent litigation involving a satralizumab biosimilar. The absence of litigation does not eliminate future risk. Biosimilar activity will depend on market size, manufacturing economics, physician switching, and the remaining enforceable patent claims.

What formulation and manufacturing barriers protect Enspryng?

Enspryng’s subcutaneous presentation creates commercial and technical barriers beyond the antibody sequence. Relevant development requirements include:

  • High-concentration protein formulation.
  • Stability during refrigerated storage.
  • Control of aggregation and particulates.
  • Consistent glycosylation and charge variants.
  • Device compatibility and injection performance.
  • Cell-line and purification-process reproducibility.
  • Comparability data for a biosimilar application.
  • Immunogenicity assessment.

A biosimilar sponsor must establish a high degree of similarity through analytical characterization, pharmacokinetic and immunogenicity studies, and, depending on FDA requirements, additional clinical evidence. Manufacturing scale and device development can materially affect launch timing and cost.

Formulation and process patents may delay a direct copy of the commercial presentation even after core antibody claims expire. They are less likely to prevent all biosimilar entry if the competitor can use a non-infringing formulation, alternative device, or different manufacturing process.

What litigation and settlement risks affect Enspryng?

No major publicly reported U.S. patent settlement involving a satralizumab biosimilar has established a market-entry date. Future disputes could arise under the BPCIA and in district court.

Likely litigation issues include:

  • Validity of antibody composition claims.
  • Written-description and enablement challenges.
  • Obviousness of satralizumab sequence or antibody class claims.
  • Infringement of AQP4-positive NMOSD method claims.
  • Dosing-regimen claims.
  • Formulation and device claims.
  • Patent-term adjustment and terminal-disclaimer calculations.
  • Carve-out strategies for protected indications.

A settlement could permit an early biosimilar launch before the last asserted patent expires. The economic value of such a settlement would depend on the size of the eligible U.S. NMOSD population, expected price erosion, and the number of competing biosimilars.

What licensing deals affect Enspryng?

Satralizumab originated within Chugai’s antibody research platform and was developed commercially through the Roche-Chugai relationship. Roche markets the product internationally outside territories retained by Chugai, while Chugai has historically retained important rights in Japan and related markets. [6]

The relationship gives Roche access to Chugai’s antibody technology while allowing Chugai to participate in commercialization and regional economics. It also means revenue attribution, patent ownership, and commercialization rights can differ by territory.

No major third-party licensing transaction has materially changed Enspryng’s competitive position in the way that Roche’s acquisition of a separate biotech platform would. The central strategic relationship remains Roche and Chugai.

What is the geographic coverage for Enspryng?

Enspryng has been approved in the United States, Europe, Japan, and other markets. Geographic performance depends on local reimbursement, diagnostic capacity, specialist access, and the availability of competing biologics.

The strongest commercial markets are likely to be:

  • United States, because of high biologic pricing and specialist treatment concentration.
  • Japan, because of Chugai’s local commercial position.
  • Western Europe, where reimbursement and national health technology assessment determine uptake.
  • Other developed markets with established neuroimmunology centers.

Emerging markets have lower near-term revenue potential because NMOSD diagnosis is limited and reimbursement for orphan biologics is uneven.

How strong is the Enspryng patent estate?

The Enspryng estate is commercially meaningful but not impenetrable. Its strengths are the biologic regulatory framework, orphan indication, antibody composition protection, specialized manufacturing, and the lack of a conventional generic pathway.

Its weaknesses are the small patient population, the possibility of biosimilar entry after statutory exclusivity, competition from mechanistically different biologics, and the ability of competitors to design around formulation or method claims.

Overall assessment:

Dimension Assessment
Regulatory protection Strong through approximately 2032-2033
Orphan exclusivity Meaningful, but limited to the same orphan use
Composition protection Likely the most valuable patent layer
Method-of-use protection Relevant to label and indication disputes
Formulation protection Potentially useful but design-around risk exists
Biosimilar risk before 2032 Low
Biosimilar risk after 2032-2033 Increasing
Competitive substitution risk Present throughout the product life cycle
Commercial concentration risk High because the indication is rare

What generic and biosimilar launch scenarios exist for Enspryng?

The most likely launch sequence is:

  1. Continued branded growth through the late 2020s.
  2. Increasing competition from Uplizna, Ultomiris, and Soliris.
  3. Patent and BPCIA activity approaching 2032.
  4. Potential first satralizumab biosimilar entry around or after the end of reference-product exclusivity, depending on enforceable patents and settlement terms.
  5. Progressive price erosion as additional biosimilars enter.

A first biosimilar could have limited impact if Roche maintains strong physician preference and payer control. A multi-biosimilar market would create greater net-price pressure. Because the total NMOSD population is small, the market may support only a limited number of economically viable biosimilar entrants.

Key Takeaways

  • Enspryng is Roche’s satralizumab biologic for AQP4-IgG-positive NMOSD.
  • Roche-reported sales rose from approximately CHF 0.2 billion in 2022 to approximately CHF 0.4 billion in 2024.
  • The product’s U.S. 12-year biologic exclusivity period runs from August 2020 to approximately August 2032.
  • Pediatric exclusivity could extend effective regulatory protection by six months.
  • Enspryng is governed by the Purple Book and BPCIA, not the conventional Orange Book and Paragraph IV process.
  • The strongest protection comes from the antibody composition estate, regulatory exclusivity, manufacturing complexity, and orphan-drug economics.
  • Uplizna is the closest commercial competitor, while Soliris and Ultomiris compete through complement inhibition.
  • No major public U.S. biosimilar litigation or settlement has established an Enspryng entry date.
  • Long-term revenue depends more on treatment penetration, persistence, and competitive positioning than on broad disease prevalence.
  • The product has a favorable growth profile but remains exposed to a small addressable population and eventual biosimilar price erosion.

FAQs

Is Enspryng a blockbuster biologic?

No. Enspryng is a growing specialty biologic with approximately CHF 0.4 billion in Roche-reported 2024 sales. It is commercially important but materially smaller than Roche’s largest products.

Can a generic version of Enspryng be approved?

No conventional generic route applies. A competitor would generally need to pursue the FDA biosimilar pathway under the Public Health Service Act.

Does Enspryng have orphan-drug exclusivity?

Yes. Enspryng received orphan-drug protection for its NMOSD indication. The seven-year U.S. orphan period began with the August 2020 approval, subject to the statutory orphan framework.

What is the main commercial advantage of Enspryng?

Its principal advantage is subcutaneous administration, which can reduce infusion-center dependence and support home treatment. Its main limitation is the need for regular injections and its use in a narrow seropositive NMOSD population.

Who owns Enspryng rights in Japan?

Chugai has retained important Japanese rights associated with satralizumab, while Roche commercializes the product in other major territories under the Roche-Chugai relationship.

References

  1. U.S. Food and Drug Administration. (2024). Enspryng (satralizumab-mwge) prescribing information.
  2. Roche Holding AG. (2022). Annual report 2022.
  3. Roche Holding AG. (2023). Annual report 2023.
  4. Roche Holding AG. (2024). Annual report 2024.
  5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
  6. Chugai Pharmaceutical Co., Ltd. (2024). Annual report 2024.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.